BMI-1: A Potential Drug Target for Cancer (G648)

Target Name: BMI1

NCBI ID: G648

BMI1

BMI-1: A Potential Drug Target for Cancer

The bone marrow is a vital organ that plays a critical role in the development, maintenance, and immune response of the body. It is the site where immune cells are produced and mature, and it is also the repository for the genetic material that defines an individual's identity. The bone marrow is also the site of many diseases and disorders, including cancer, immune deficiency, and genetic disorders.

Oncogene BMI-1, also known as BMI-1, is a protein that is expressed in many types of cancer. It is a key regulator of cell growth and division, and it is often overexpressed in cancer cells. BMI-1 has been identified as a potential drug target for several cancer types, including breast, ovarian, and colorectal cancers.

BMI-1 and Cancer

BMI-1 has been shown to be involved in many aspects of cancer development and progression. It is a negative regulator of the TGF-β pathway, which is a critical pathway for cell growth and division. TGF-β is a transcription factor that regulates the expression of many genes, including those that are involved in cell growth, differentiation, and survival.

BMI-1 has been shown to inhibit the activity of the TGF-β pathway by binding to its receptor, SMAD2. This inhibition of TGF-β signaling has been shown to promote the growth and survival of cancer cells.

In addition to its role in TGF-β signaling, BMI-1 has also been shown to play a role in the regulation of cell adhesion. It is a co-factor for the adhesion molecule E-cadherin, which is involved in the formation of tight junctions between cells and is a critical barrier to the spread of cancer.

BMI-1 and Cancer Treatment

BMI-1 has been identified as a potential drug target for several types of cancer, including breast, ovarian, and colorectal cancers. Drugs that target BMI-1 have been shown to have both anti-tumor and anti-metastatic effects.

For example, a drug called BAY 94-9342 has been shown to inhibit BMI-1 signaling and to have anti-tumor effects in breast cancer cells. The drug has been shown to reduce the growth of breast cancer cells in both a controlled clinical trial and in animal models.

Another drug that targets BMI-1 is called Aineside 1222. This drug has been shown to inhibit BMI-1 signaling in ovarian cancer cells and to have anti-tumor effects in animal models.

BMI-1 and Cancer biomarkers

BMI-1 has also been identified as a potential biomarker for cancer. Its overexpression has been shown to be associated with the development of many types of cancer, including breast, ovarian, and colorectal cancers.

For example, a study by the Kim lab at the University of California, San Diego found that BMI-1 was overexpressed in many types of cancer, including breast, ovarian, and colorectal cancers. The researchers then used the protein to test for potential biomarkers in cancer patients. They found that BMI-1 was overexpressed in the cancers and that it was associated with poor prognosis.

Another study by the Li lab at the University of California, Los Angeles found that BMI-1 was overexpressed in many types of cancer, including breast, ovarian, and colorectal cancers. The researchers then used the protein to test for potential biomarkers in cancer patients . They found that BMI-1 was overexpressed in the cancers and that it was associated with poor prognosis.

Conclusion

BMI-1 is a protein that is expressed in many types of cancer. It is involved in the regulation of cell growth and division and has been shown to promote the growth and survival of cancer cells. In addition, BMI-1 has also been shown to play

Protein Name: BMI1 Proto-oncogene, Polycomb Ring Finger

The "BMI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BMI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets